TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 794558
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation alone (0.5 to 0.75 g/day)
Study: 23561712
Drug: Silodosin 8
Normalized name: silodosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 8 mg once daily for 3 days
Study: 21364527
Drug: Cognitive‐behavioural group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioural group treatment (eight sessions)
Study: 17374657
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (42 g)
Study: 17374657
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (1 g)
Study: 18772641
Drug: lumiracoxib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: lumiracoxib 400 mg once daily
Study: 15325832
Drug: ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 800 mg three times daily
Study: 11251007
Drug: Granisetron (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (10 microg/kg IV) + Dexamethasone (20 mg PO)
Study: 11251007
Drug: Granisetron (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (10 microg/kg IV) + MK-869 (400 mg PO pre-cisplatin, 300 mg PO days 2-5) + Dexamethasone (20 mg PO)
Study: 11251007
Drug: MK-869 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-869 (400 mg PO evening before and pre-cisplatin, 300 mg PO days 2-5) + Dexamethasone (20 mg PO)
Study: 11251007
Drug: MK-869 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-869 (400 mg PO pre-cisplatin, 300 mg PO days 2-5) + Dexamethasone (20 mg PO)
Study: 8281644
Drug: Autonomic blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autonomic blockade using 0.04 mg/kg atropine and 0.2 mg/kg propranolol
Study: 2253535
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g four times a day
Study: 2660561
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sucralfate 1 g three times a day and 400 mg cimetidine at night
Study: 2660561
Drug: Sucralfate maintenance
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate maintenance 2 g daily
Study: 21552054
Drug: Topical sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical sucralfate (7% sucralfate ointment applied twice daily for 6 weeks)
Study: 21552054
Drug: Placebo (petroleum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (petroleum jelly ointment applied twice daily for 6 weeks)
Study: 21658805
Drug: Topical sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical sucralfate
Study: 19803236
Drug: Herbal steaming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal steaming and washing therapy
Study: 19803236
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment (Vitamin B1, Vitamin B12, compound Vitamin B, small splint for wrist protection)
Study: 18829444
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (0.625 mg/d)
Study: 15031611
Drug: Ebastine 20
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 20 mg (E20)
Study: 12731456
Drug: Ebastine 10
Normalized name: ebastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10 mg (E10)
Study: 15160440
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg (L10)
Study: 8186349
Drug: famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 40 mg b.d.
Study: 8186349
Drug: famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 20 mg b.d.
Study: 3285836
Drug: Torasemide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (200 mg/day)
Study: 3285836
Drug: Furosemide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (500 mg/day)
Study: 28005003
Drug: Letter sent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letter sent from GP to parents/carers reminding about medication (n=70 practices)
Study: 22858176
Drug: PEG‐IFN alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN alfa‐2a 180 μg SC
Study: 22858176
Drug: PEG‐IFN alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN alfa‐2a 90 μg IV
Study: 19324346
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) 6-g bolus IV followed by 2 g/h baseline
Study: 12495098
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine infusion at 2 mL/hr for 48 hours plus PCA morphine
Study: 7663867
Drug: PCA morphine
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA morphine only
Study: 10622581
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN) alone at standard dosage (3 MU t.i.w.) for 12 months
Study: 10622581
Drug: Ribavirin as
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin as single therapy at standard dosage (15 mg/kg bodyweight in two divided doses daily)
Study: 10622581
Drug: Ribavirin in
Normalized name: ribavirin Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin in combination with interferon alpha at standard doses for 6-12 months
Study: 7749168
Drug: Navoban (tropisetron)
Normalized name: benzocaine / trimethobenzamide hydrochloride Rectal Suppository [Navogan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navoban (tropisetron) monotherapy
Study: 161170
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs in combination (IF)
Study: 31927026
Drug: Simethicone 160
Normalized name: simethicone 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone 160 mg with 50 mL water, administered 2-8 hours before surgery
Study: 30636701
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg methylcobalamin
Study: 30636701
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg methylcobalamin
Study: 27281727
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL interscalene nerve block
Study: 27281727
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL interscalene nerve block
Study: 24679400
Drug: Venlafaxine-extended-release
Normalized name: venlafaxine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine-extended-release
Study: 21931122
Drug: Paricalcitol (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (IV or oral depending on site)
Study: 20032789
Drug: PCB +
Normalized name: Procarbazine
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCB + S (25 mg daily, 2 weeks on, 1 week off)
Study: 20032789
Drug: PCB (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCB (15 mg/kg every 3 weeks)
Study: 12204648
Drug: Low-intensity laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity laser irradiation (HeNe, 632.8 nm) with a dose of 30 J/cm²
Study: 10494759
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy with targeted INR of 2.0 to 2.5
Study: 10494759
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy with targeted INR of 1.5 to 1.9
Study: 8610715
Drug: Metaproterenol (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol (5% solution, 15 mg)
Study: 1487306
Drug: Partner-specific leukocyte
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partner-specific leukocyte immunotherapy
Study: 1487306
Drug: Own cells
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Own cells immunotherapy
Study: 4035297
Drug: Oral water
Normalized name: Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral water
Study: 4035297
Drug: Exogenous infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous infusions of porcine motilin (physiological and pharmacological)
Study: 31601166
Drug: Attending 12
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Attending 12 or less number of patients daily
Study: 19589288
Drug: Nasal irrigation
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal irrigation with Lavonase system (250 mL saline solution sac, twice daily for 14 days)
Study: 19589288
Drug: Nasal syringe
Normalized name: nasal syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal syringe (10 mL saline solution, 3 times daily for 14 days)
Study: 1955814
Drug: Diazepam (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0 mg, 7.5 mg, 15 mg, 30 mg/70 kg, p.o.)
Study: 1955814
Drug: Triazolam (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0 mg, 0.375 mg, 0.75 mg/70 kg, p.o.)
Study: 8207316
Drug: Indobufen 200
Normalized name: indobufen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen 200 mg twice daily
Study: 7134226
Drug: Indobufen (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (higher dosage)
Study: 27832646
Drug: 400 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 µg folic acid (control group); n = 50
Study: 25301018
Drug: Patient knowledge
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient knowledge of medical condition and treatment options
Study: 22532053
Drug: Group interpersonal
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group interpersonal psychotherapy (IPT-G)
Study: 15161357
Drug: Chronic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chronic low-dose whole-body ionizing radiation exposure
Study: 9546804
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) and didanosine (ddI) therapy
Study: 10488481
Drug: no therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: no therapy
Study: 1707338
Drug: Concomitant radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant radiation therapy and chemotherapy (RT + CT) with 5‐fluorouracil (5‐FU), mitomycin C, and bleomycin
Study: 7009256
Drug: Conventional oxprenolol
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional oxprenolol administered twice daily
Study: 7009256
Drug: Slow-release oxprenolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release oxprenolol administered once daily
Study: 7009256
Drug: Cyclopenthiazide 0.5
Normalized name: cyclopenthiazide 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclopenthiazide 0.5 mg daily (in 16 patients)
Study: 9709721
Drug: 7-valent pneumococcal-conjugate
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal-conjugate vaccine plus 23-valent pneumococcal vaccine
Study: 9709721
Drug: 23-valent vaccine
Normalized name: Pneumococcal 23-valent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent vaccine only
Study: 3276900
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy with 5‐fluorouracil, semustine, and vincristine (MOF) (187 patients)
Study: 3276900
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (4,600‐4,700 rad in 26‐27 fractions; 5,100‐5,300 rad maximum at the perineum) (184 patients)
Study: 3276900
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (184 patients)
Study: 21668683
Drug: Ann Arbor
Normalized name: Hemoglobin Ann Arbor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ann Arbor strain live attenuated influenza vaccine (LAIV)
Study: 1401653
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg)
Study: 8464431
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg once daily)
Study: 1392444
Drug: Urodilatin (CDD/ANP‐95‐126)
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urodilatin (CDD/ANP‐95‐126) administered in a long‐term, low‐dose infusion (6‐20 ng/kg bw.min) for 96 hours after HTx
Study: 30987415
Drug: Intraperitoneal nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal nebulization of 5 ml 1% ropivacaine before and after surgery
Study: 30987415
Drug: Intraperitoneal instillation
Normalized name: Taurolidine 20 mg/mL solution for intraperitoneal instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal instillation of 20 ml 0.5% ropivacaine after induction of pneumoperitoneum
Study: 30987415
Drug: Intraperitoneal nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal nebulization of 5 ml 1% ropivacaine
Study: 25144296
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 60 mg and Candesartan cilexetil 32 mg
Study: 25144296
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (any dose) and Candesartan cilexetil (any dose)
Study: 25144296
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 20 mg and Candesartan cilexetil 4 mg
Study: 9758086
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS monotherapy
Study: 25144296
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS plus Candesartan cilexetil combination therapy
Study: 20067715
Drug: Focused extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Focused extracorporeal shock wave therapy (0.20 mJ/mm(2))
Study: 20067715
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (0.17 mJ/mm(2))
Study: 7494110
Drug: Prednisolone plus
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone plus a beta‐lactamase stable antibiotic for 10 days, with responders receiving an additional six weeks of chemoprophylaxis.
Study: 7494110
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (Control group).
Study: 7494110
Drug: Prednisolone plus
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone plus a beta‐lactamase stable antibiotic.
Study: 7439263
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of ketoprofen (capsule)
Study: 7439263
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of ketoprofen
Study: 7439263
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of ketoprofen (suppository)
Study: 7439263
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of ketoprofen
Study: 7439263
Drug: Repeated oral
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated oral administration of ketoprofen (50 mg q.i.d.)
Study: 7439263
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of ketoprofen
Study: 31815790
Drug: New clinical
Normalized name: octinoxate 75 mg in 1 g / oxybenzone 40 mg in 1 g / avobenzone 20 mg in 1 g TOPICAL CREAM [Anew Clinical Absolute Even Spot Correcting Hand]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New clinical endpoints focusing on treatment safety and patient quality of life.
Study: 28178008
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional cooling treatment (Control)
Study: 25808994
Drug: CNI-free (everolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI-free (everolimus with half-dose EC-MPS 720 mg/day and cyclosporine withdrawal)
Study: 23668026
Drug: Decoction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decoction of invigorating Qi and clearing lung combined with standardized myrtol (300 mg, 3 times a day)
Study: 23668026
Drug: Standardized myrtol
Normalized name: myrtol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized myrtol (300 mg, 3 times a day)
Study: 21030470
Drug: Sustained seating
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained seating force during bonding (300 g for 3 seconds, maintained for 40 seconds during curing)
Study: 21030470
Drug: Initial seating
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial seating force (300 g for 3 seconds, no sustained force)
Study: 26606872
Drug: Traditional swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional swallowing therapy
Study: 17592789
Drug: Ziprasidone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (80 mg/day)
Study: 17592789
Drug: Ziprasidone (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (160 mg/day)
Study: 17592789
Drug: Ziprasidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (mean dose)
Study: 11588528
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg, once daily)
Study: 11588528
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg, once daily)
Study: 9849987
Drug: Three dose
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dose primary schedule (2, 4, 6 months)
Study: 9849987
Drug: Two dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two dose primary schedule (3, 5 months)
Study: 7851356
Drug: Neostigmine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine and methyl-atropine administered 2 minutes after rocuronium (Group B)
Study: 7851356
Drug: Neostigmine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine and methyl-atropine administered at 25% twitch recovery (Group C)
Study: 7851356
Drug: Neostigmine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine and methyl-atropine administered at spontaneous recovery (Group A)
Study: 68454
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) injection of bleomycin
Study: 68454
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) injection of bleomycin
Study: 26482136
Drug: Therapeutic Educational
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic Educational System (TES) with Contingency Management (CM) component, earning up to $600 in prizes over 12 weeks for providing drug negative urines and completing web-based cognitive behavior therapy modules.
Study: 25174443
Drug: Bioline® (albumin-heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioline® (albumin-heparin coating)
Study: 23740194
Drug: Triple antioxidant
Normalized name: Ascorbic Acid/Vitamin A/Vitamin E 250 MG-5000 IU-200 IU Oral Tablet [TRIPLE ANTIOXIDANT FORMULA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antioxidant therapy (allopurinol, α-lipoic acid, and nicotinamide)
Study: 9223025
Drug: L‐NMMA 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA 4.0 mumol/min i.v.
Study: 9223025
Drug: L‐arg (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐arg (30 mumol/kg‐min i.v.)
Study: 8335541
Drug: High-carbohydrate diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate diet (10 g/kg body wt)
Study: 8335541
Drug: Moderate-carbohydrate diet
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-carbohydrate diet (5 g/kg body wt)
Study: 2952606
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and intracoronary thrombolysis with transluminal coronary angioplasty
Study: 2952606
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and intracoronary thrombolysis without transluminal coronary angioplasty
Study: 29878035
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg vitamin D3/d (400 IU)
Study: 29878035
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg vitamin D3/d (800 IU)
Study: 29878035
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 µg vitamin D3/d)
Study: 27394029
Drug: Follow-up antibody
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up antibody testing after RBC transfusions
Study: 27394029
Drug: No follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: No follow-up antibody screen or testing too soon (<30 days) after transfusion
Study: 22340993
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 10mg/kg as a bolus preoperatively followed by 1mg/kg as a maintenance dose intra operatively
Study: 20206835
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg/day for 8 weeks